• 1. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 2. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Phthalides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Isobenzofuranones Phthalides

O-Methyl Mycophenolate Mofetil (EP Impurity D) – A Comprehensive Guide to Its Properties and Applications

O-Methyl Mycophenolate Mofetil (EP Impurity D), with the CAS number 1322681-37-7, is a critical impurity in the synthesis and quality control of pharmaceutical compounds. This compound is structurally related to Mycophenolate Mofetil (MMF), a widely used immunosuppressive drug. Understanding its properties, applications, and regulatory implications is essential for researchers, pharmaceutical manufacturers, and quality control professionals.

The chemical structure of O-Methyl Mycophenolate Mofetil (EP Impurity D) features a methyl group substitution, distinguishing it from the parent compound. This modification impacts its physicochemical properties, including solubility, stability, and chromatographic behavior. As an EP Impurity, it is closely monitored in pharmaceutical formulations to ensure compliance with stringent regulatory standards set by organizations like the European Pharmacopoeia (EP) and the U.S. Pharmacopeia (USP).

One of the most searched questions in the pharmaceutical industry is: "What are the common impurities in Mycophenolate Mofetil?" O-Methyl Mycophenolate Mofetil (EP Impurity D) is among the key impurities that must be quantified during drug development and manufacturing. Analytical techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) are commonly employed to detect and quantify this impurity at trace levels.

The significance of O-Methyl Mycophenolate Mofetil (EP Impurity D) extends to its role in pharmaceutical stability studies. Researchers often investigate how storage conditions, such as temperature and humidity, affect the formation of this impurity. Recent trends in the pharmaceutical industry emphasize the importance of impurity profiling to enhance drug safety and efficacy, making this compound a focal point in quality assurance protocols.

In addition to its regulatory relevance, O-Methyl Mycophenolate Mofetil (EP Impurity D) is also studied for its potential biological activity. While it is primarily considered an impurity, some researchers explore its pharmacological properties to understand its impact on the therapeutic profile of Mycophenolate Mofetil. This dual role highlights the compound's importance in both pharmaceutical quality control and biomedical research.

The market for pharmaceutical reference standards has seen growing demand for high-purity O-Methyl Mycophenolate Mofetil (EP Impurity D). Suppliers and manufacturers are increasingly focusing on producing certified reference materials (CRMs) to support analytical testing and compliance with global pharmacopeial standards. This trend aligns with the broader emphasis on quality by design (QbD) in drug development.

Another hot topic in the pharmaceutical community is the impact of impurities on biosimilars and generics. As the industry shifts toward cost-effective alternatives to branded drugs, ensuring the consistency and purity of active pharmaceutical ingredients (APIs) becomes paramount. O-Methyl Mycophenolate Mofetil (EP Impurity D) serves as a critical marker in this context, helping manufacturers maintain the quality and performance of their products.

For researchers working on Mycophenolate Mofetil-based therapies, understanding the synthesis pathways that lead to the formation of O-Methyl Mycophenolate Mofetil (EP Impurity D) is crucial. Process optimization and robust analytical methods are key to minimizing its presence in final drug products. Recent advancements in green chemistry and sustainable manufacturing practices also aim to reduce impurity formation while improving yield and efficiency.

In conclusion, O-Methyl Mycophenolate Mofetil (EP Impurity D) (CAS: 1322681-37-7) plays a vital role in pharmaceutical quality control, regulatory compliance, and research. Its study not only ensures the safety and efficacy of Mycophenolate Mofetil-based drugs but also contributes to the broader understanding of impurity behavior in complex formulations. As the pharmaceutical industry continues to evolve, the importance of such impurities in drug development and manufacturing will only grow.

• 128794-94-5(Mycophenolate mofetil)
• 224052-51-1(Mycophenolate Mofetil N-Oxide (EP Impurity G))
• 1322681-36-6(O-Desmethyl Mycophenolate Mofetil(Impurity A))
• 1094322-91-4(1-[2-(4-Morpholinyl)ethoxy])
• 115007-34-6(Mycophenolate mofetil)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)